PMZ-2010 (Centhaquine) as a Resuscitative Agent for Hypovolemic Shock
Status:
Completed
Trial end date:
2018-10-21
Target enrollment:
Participant gender:
Summary
This is a prospective, multi-centric, randomized, double-blind, parallel, controlled phase-II
efficacy clinical study of PMZ-2010 therapy in patients with hypovolemic shock.
Centhaquine is highly safe and well tolerated. Toxicological studies showed high safety
margin in preclinical studies. Its safety and tolerability has been demonstrated in a human
phase I study in 25 subjects (CTRI/2014/06/004647; NCT02408731).